The challenges in treating AML with CAR T-cell therapy

CAR T-cell Therapy in AML: State of the ArtПодробнее

What are the challenges associated with CAR T-cell therapy in patients with AML?Подробнее

CAR T for Acute Myeloid Leukemia with Dr Marco Davila—Molecular Therapy PodcastПодробнее

The challenges with implementing CAR-T into the AML treatment landscapeПодробнее

CAR-T therapy in AML: why has there been a lack of success?Подробнее

Key challenges in immunotherapy for AMLПодробнее

CAR-T Revolution: Unleashing the Immune Power Against CancerПодробнее

Insights into NKG2D-targeting CAR-T cells in R/R AMLПодробнее

Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cellsПодробнее

IL3-zetakine coupled to a CD33 costimulatory receptor as a dual-targeting CAR approach in AMLПодробнее

Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cellsПодробнее

Hurdles to CAR-T therapy for MDS & AML: T-cell fitness & lack of a uniform target antigenПодробнее

Challenges in Treating TP53-Mutated AML, Hope on the HorizonПодробнее

The potential of bringing CAR-T therapy to MDS and challenges to overcomeПодробнее

The challenges of implementing CAR-T therapy in CLLПодробнее

Remaining challenges in treating ALL with CAR-T therapyПодробнее

Future prospects for CAR-T cell therapy in AMLПодробнее

The challenges of using CAR-T cell therapy to treat patients with CLLПодробнее

Recent advances in CAR-T therapy for MDSПодробнее

Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…Подробнее